UY27350A1 - Azaindoles - Google Patents

Azaindoles

Info

Publication number
UY27350A1
UY27350A1 UY27350A UY27350A UY27350A1 UY 27350 A1 UY27350 A1 UY 27350A1 UY 27350 A UY27350 A UY 27350A UY 27350 A UY27350 A UY 27350A UY 27350 A1 UY27350 A1 UY 27350A1
Authority
UY
Uruguay
Prior art keywords
compounds
prodrugs
compositions
formula
azaindols
Prior art date
Application number
UY27350A
Other languages
English (en)
Spanish (es)
Inventor
P Cox
T Majid
J Lai
A Morley
S Amendola
S Deprets
C Edlin
C Gardner
D Kominos
B Pedgrift
F Halley
T Gillespy
M Edwards
F Clerc
C Nemecek
O Houille
D Damour
H Bouchard
D Bezard
C Carrez
Original Assignee
Aventis Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Ltd filed Critical Aventis Pharma Ltd
Publication of UY27350A1 publication Critical patent/UY27350A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
UY27350A 2001-06-21 2002-06-21 Azaindoles UY27350A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0115109.1A GB0115109D0 (en) 2001-06-21 2001-06-21 Chemical compounds
US30025701P 2001-06-22 2001-06-22

Publications (1)

Publication Number Publication Date
UY27350A1 true UY27350A1 (es) 2003-04-30

Family

ID=9917016

Family Applications (1)

Application Number Title Priority Date Filing Date
UY27350A UY27350A1 (es) 2001-06-21 2002-06-21 Azaindoles

Country Status (37)

Country Link
US (2) US6897207B2 (cg-RX-API-DMAC7.html)
EP (2) EP1397360A1 (cg-RX-API-DMAC7.html)
JP (1) JP4409938B2 (cg-RX-API-DMAC7.html)
KR (2) KR100915289B1 (cg-RX-API-DMAC7.html)
CN (1) CN100509811C (cg-RX-API-DMAC7.html)
AP (1) AP1739A (cg-RX-API-DMAC7.html)
AR (1) AR036106A1 (cg-RX-API-DMAC7.html)
BG (1) BG108481A (cg-RX-API-DMAC7.html)
BR (1) BR0210507A (cg-RX-API-DMAC7.html)
CA (1) CA2451678C (cg-RX-API-DMAC7.html)
CZ (1) CZ20033444A3 (cg-RX-API-DMAC7.html)
EC (1) ECSP034914A (cg-RX-API-DMAC7.html)
EE (1) EE200400015A (cg-RX-API-DMAC7.html)
GB (1) GB0115109D0 (cg-RX-API-DMAC7.html)
HN (1) HN2002000154A (cg-RX-API-DMAC7.html)
HR (1) HRP20031069A2 (cg-RX-API-DMAC7.html)
HU (1) HUP0400247A2 (cg-RX-API-DMAC7.html)
IL (1) IL159445A0 (cg-RX-API-DMAC7.html)
JO (1) JO2327B1 (cg-RX-API-DMAC7.html)
MA (1) MA27043A1 (cg-RX-API-DMAC7.html)
MY (1) MY137099A (cg-RX-API-DMAC7.html)
NO (1) NO20035476D0 (cg-RX-API-DMAC7.html)
NZ (2) NZ545741A (cg-RX-API-DMAC7.html)
OA (1) OA12637A (cg-RX-API-DMAC7.html)
PA (1) PA8548701A1 (cg-RX-API-DMAC7.html)
PE (1) PE20030155A1 (cg-RX-API-DMAC7.html)
PL (1) PL365067A1 (cg-RX-API-DMAC7.html)
RU (1) RU2326880C2 (cg-RX-API-DMAC7.html)
SI (1) SI21462A (cg-RX-API-DMAC7.html)
SK (1) SK15902003A3 (cg-RX-API-DMAC7.html)
TN (1) TNSN03110A1 (cg-RX-API-DMAC7.html)
TW (1) TWI334417B (cg-RX-API-DMAC7.html)
UA (1) UA85660C2 (cg-RX-API-DMAC7.html)
UY (1) UY27350A1 (cg-RX-API-DMAC7.html)
WO (1) WO2003000688A1 (cg-RX-API-DMAC7.html)
YU (1) YU96903A (cg-RX-API-DMAC7.html)
ZA (1) ZA200309648B (cg-RX-API-DMAC7.html)

Families Citing this family (235)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20020547B1 (hr) 1999-12-24 2011-06-30 Aventis Pharma Limited Azaindoli
GB0115109D0 (en) 2001-06-21 2001-08-15 Aventis Pharma Ltd Chemical compounds
EP2335700A1 (en) * 2001-07-25 2011-06-22 Boehringer Ingelheim (Canada) Ltd. Hepatitis C virus polymerase inhibitors with a heterobicylic structure
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
GB0202679D0 (en) * 2002-02-05 2002-03-20 Glaxo Group Ltd Novel compounds
TW200307542A (en) * 2002-05-30 2003-12-16 Astrazeneca Ab Novel compounds
MXPA05001688A (es) 2002-08-12 2005-04-19 Sugen Inc 3-pirrolil-piridopirazoles y 3-pirrolil-indazoles como inhibidores de cinasa novedosos.
SE0202463D0 (sv) * 2002-08-14 2002-08-14 Astrazeneca Ab Novel compounds
US20050288299A1 (en) * 2002-10-09 2005-12-29 Mavunkel Babu J Azaindole derivatives as inhibitors of p38 kinase
US20050043212A1 (en) * 2002-10-09 2005-02-24 Ford Kirschenbaum Differential inhibition of p38 map kinase isoforms
RU2005114010A (ru) * 2002-10-09 2006-01-20 Сайос Инк. (Us) Производные азаиндола в качестве ингибиторов киназы р38
US7098231B2 (en) * 2003-01-22 2006-08-29 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
US7223785B2 (en) 2003-01-22 2007-05-29 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
GB0305142D0 (en) * 2003-03-06 2003-04-09 Eisai London Res Lab Ltd Synthesis
SE0301372D0 (sv) * 2003-05-09 2003-05-09 Astrazeneca Ab Novel compounds
CA2530679A1 (en) * 2003-06-30 2005-04-07 Hif Bio, Inc. Compounds for treating angiogenesis
US7202363B2 (en) 2003-07-24 2007-04-10 Abbott Laboratories Thienopyridine and furopyridine kinase inhibitors
PT1656372E (pt) 2003-07-30 2013-06-27 Rigel Pharmaceuticals Inc Métodos para o tratamento ou prevenção de doenças autoimunes com compostos de 2,4-pirimidinadiamina
WO2005056547A2 (en) 2003-12-04 2005-06-23 Vertex Pharmaceuticals Incorporated Quinoxalines useful as inhibitors of protein kinases
WO2005061519A1 (en) 2003-12-19 2005-07-07 Takeda San Diego, Inc. Kinase inhibitors
PT1718608E (pt) * 2004-02-20 2013-08-01 Boehringer Ingelheim Int Inibidores da polimerase viral
US7507826B2 (en) * 2004-03-30 2009-03-24 Vertex Pharmaceuticals Incorporated Azaindoles useful as inhibitors of JAK and other protein kinases
FR2868422B1 (fr) * 2004-03-31 2006-07-14 Aventis Pharma Sa Nouveaux derives pyrrolo(2,3-b) pyridine, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
US7608627B2 (en) * 2004-04-05 2009-10-27 Takeda Pharmaceutical Company Limited 6-azaindole compound
WO2005105788A1 (en) * 2004-04-23 2005-11-10 Takeda San Diego, Inc. Indole derivatives and use thereof as kinase inhibitors
EP2264033A1 (en) * 2004-07-27 2010-12-22 SGX Pharmaceuticals, Inc. 3,5-DIPHENYL-SUBSTITUTED PYRROLO[2,3b]PYRIDINES USEFUL AS KINASE INHIBITORS
EP1781664B1 (en) * 2004-07-30 2013-09-04 MethylGene Inc. Inhibitors of vegf receptor and hgf receptor signaling
WO2006017443A2 (en) * 2004-08-02 2006-02-16 Osi Pharmaceuticals, Inc. Aryl-amino substituted pyrrolopyrimidine multi-kinase inhibiting compounds
JP2008510734A (ja) 2004-08-18 2008-04-10 タケダ サン ディエゴ インコーポレイテッド キナーゼ阻害剤
EP1786777A1 (en) * 2004-08-26 2007-05-23 Pfizer, Inc. Aminoheteroaryl compounds as protein tyrosine kinase inhibitors
FR2876103B1 (fr) * 2004-10-01 2008-02-22 Aventis Pharma Sa Nouveaux derives bis-azaindoles, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
JP2008516973A (ja) 2004-10-15 2008-05-22 タケダ サン ディエゴ インコーポレイテッド キナーゼ阻害剤
MY179032A (en) * 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
NZ555566A (en) * 2004-11-22 2009-12-24 Vertex Pharma Pyrrolopyrazines and pyrazolopyrazines useful as inhibitors of protein kinases
US20090233955A1 (en) * 2004-12-08 2009-09-17 Frazee James S 1H-Pyrrolo[2,3-B]Pyridnes
AR054416A1 (es) * 2004-12-22 2007-06-27 Incyte Corp Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas.
WO2006066914A2 (en) * 2004-12-23 2006-06-29 F. Hoffmann-La Roche Ag Carbamate substituted imidazo- and pyrrolo-pyridines as protein kinase inhibitors
AU2006239632B2 (en) * 2005-04-25 2012-03-15 Merck Patent Gmbh Novel AZA- heterocycles serving as kinase inhibitors
FR2884821B1 (fr) 2005-04-26 2007-07-06 Aventis Pharma Sa Pyrrolopyridines substitues, compositions les contenant, procede de fabrication et utilisation
BRPI0610382A2 (pt) 2005-05-20 2010-06-15 Methylgene Inc inibidores de sinalização de receptor de vegf e receptor de hgf
BRPI0610322B8 (pt) 2005-05-20 2021-05-25 Methylgene Inc inibidores de sinalização de receptor de vegf e de receptor de hgf e composição farmacêutica
CA2609126A1 (en) * 2005-05-20 2006-11-30 Vertex Pharmaceuticals Incorporated Pyrrolopyridines useful as inhibitors of protein kinase
CA2607901C (en) 2005-06-13 2016-08-16 Rigel Pharmaceuticals, Inc. Methods and compositions for treating degenerative bone disorders using a syk inhibitory 2,4-pyrimidinediamine
PT1734251E (pt) * 2005-06-17 2007-03-30 Magneti Marelli Powertrain Spa Injector de combustível
BRPI0611863B1 (pt) 2005-06-22 2021-11-23 Plexxikon, Inc Composto, bem como composição e kit compreendendo o mesmo, composto intermediário na preparação do mesmo, método para tratamento e uso do mesmo
KR101142363B1 (ko) * 2005-06-27 2012-05-21 주식회사유한양행 피롤로피리딘 유도체를 포함하는 항암제 조성물
CN102127078A (zh) * 2005-07-14 2011-07-20 安斯泰来制药株式会社 Janus激酶3的杂环类抑制剂
JP5015154B2 (ja) * 2005-08-12 2012-08-29 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ウイルスポリメラーゼインヒビター
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
WO2007073432A2 (en) 2005-10-11 2007-06-28 Chemocentryx, Inc. Piperidine derivatives and methods of use
US7371862B2 (en) 2005-11-11 2008-05-13 Pfizer Italia S.R.L. Azaindolylidene derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
EP2514751A1 (en) * 2005-11-15 2012-10-24 Vertex Pharmaceuticals, Inc. Azaindazoles useful as inhibitor of kinases
US20070129364A1 (en) * 2005-12-07 2007-06-07 Han-Qing Dong Pyrrolopyridine kinase inhibiting compounds
SI2455382T1 (sl) 2005-12-13 2017-03-31 Incyte Holdings Corporation S heteroarilom substituirani pirolo(2,3b)piridini in pirolo(2,3-b)pirimidini kot zaviralci janus kinaze
CA2636929A1 (en) * 2005-12-21 2007-07-12 Decode Genetics, Ehf Biaryl nitrogen heterocycle inhibitors of lta4h for treating inflammation
WO2007084557A2 (en) 2006-01-17 2007-07-26 Vertex Pharmaceuticals Incorporated Azaindoles useful as inhibitors of janus kinases
CN101466676B (zh) 2006-04-12 2012-07-18 默沙东公司 吡啶基酰胺类t-型钙通道拮抗剂
PL2026775T3 (pl) * 2006-05-09 2015-12-31 Novaremed Ltd Zastosowanie inhibitorów kinazy tyrozynowej Syk w leczeniu komórkowych zaburzeń proliferacyjnych
CA2858520A1 (en) * 2006-05-18 2007-11-29 Pharmacyclics Inc. Intracellular kinase inhibitors
GB0617161D0 (en) * 2006-08-31 2006-10-11 Vernalis R&D Ltd Enzyme inhibitors
CL2007002617A1 (es) * 2006-09-11 2008-05-16 Sanofi Aventis Compuestos derivados de pirrolo[2,3-b]pirazin-6-ilo; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar inflamacion de las articulaciones, artritis reumatoide, tumores, linfoma de las celulas del manto.
US20100120717A1 (en) 2006-10-09 2010-05-13 Brown Jason W Kinase inhibitors
JP2010505961A (ja) * 2006-10-09 2010-02-25 タケダ サン ディエゴ インコーポレイテッド キナーゼ阻害剤
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
CN101678022A (zh) 2006-12-21 2010-03-24 弗特克斯药品有限公司 可用作蛋白激酶抑制剂的5-氰基-4-(吡咯并[2,3b]吡啶-3-基)嘧啶衍生物
PE20081581A1 (es) * 2006-12-21 2008-11-12 Plexxikon Inc COMPUESTOS PIRROLO[2,3-b]PIRIDINAS COMO MODULADORES DE QUINASA
TW200833711A (en) * 2006-12-22 2008-08-16 Genentech Inc Antibodies to insulin-like growth factor receptor
EP2141148B1 (en) 2007-03-29 2013-07-03 Daiichi Sankyo Company, Limited Indole derivative having cpla2 inhibitory activity, use of the same and method for producing the same
ES2467665T5 (es) 2007-06-13 2022-11-03 Incyte Holdings Corp Sales del inhibidor de cinasas Janus (R)-3-(4-(7H-pirrolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il)-3-ciclopentilpropanonitrilo
JP2010533729A (ja) 2007-07-17 2010-10-28 プレキシコン，インコーポレーテッド キナーゼ調節のための化合物と方法、及びそのための適応
US20110160232A1 (en) 2007-10-04 2011-06-30 Pingda Ren Certain chemical entities and therapeutic uses thereof
EP2212291B1 (en) 2007-10-24 2014-06-04 Merck Sharp & Dohme Corp. Heterocycle phenyl amide t-type calcium channel antagonists
JP2011500808A (ja) * 2007-10-24 2011-01-06 メルク・シャープ・エンド・ドーム・コーポレイション 複素環アミドｔ型カルシウムチャネルアンタゴニスト
RU2503676C2 (ru) * 2008-02-25 2014-01-10 Ф.Хоффманн-Ля Рош Аг Пирролопиразиновые ингибиторы киназы
ATE522536T1 (de) 2008-02-25 2011-09-15 Hoffmann La Roche Pyrrolopyrazin-kinasehemmer
WO2009106444A1 (en) 2008-02-25 2009-09-03 F. Hoffmann-La Roche Ag Pyrrolopyrazine kinase inhibitors
ES2372908T3 (es) 2008-02-25 2012-01-27 F. Hoffmann-La Roche Ag Inhibidores de la pirrolopirazina quinasa.
EP2247595B1 (en) * 2008-02-25 2011-07-20 F. Hoffmann-La Roche AG Pyrrolopyrazine kinase inhibitors
CN102015723B (zh) 2008-03-05 2014-07-30 梅特希尔基因公司 蛋白酪氨酸激酶活性的抑制剂
US8993580B2 (en) 2008-03-14 2015-03-31 Intellikine Llc Benzothiazole kinase inhibitors and methods of use
US8637542B2 (en) 2008-03-14 2014-01-28 Intellikine, Inc. Kinase inhibitors and methods of use
PT2300013T (pt) 2008-05-21 2017-10-31 Ariad Pharma Inc Derivados de fósforo como inibidores de cinases
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
CN102112478A (zh) * 2008-06-10 2011-06-29 普莱希科公司 用于激酶调节的5h-吡咯[2，3-b]吡嗪衍生物和其适应症
JP5788316B2 (ja) * 2008-07-08 2015-09-30 インテリカイン， エルエルシー キナーゼインヒビターおよび使用方法
US8476431B2 (en) 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
JP5590040B2 (ja) 2008-11-12 2014-09-17 アリアド・ファーマシューティカルズ・インコーポレイテッド キナーゼ阻害剤としてのピラジノピラジンおよび誘導体
KR101361858B1 (ko) * 2008-12-05 2014-02-12 에프. 호프만-라 로슈 아게 피롤로피라지닐 우레아 키나아제 저해제
MX2011005943A (es) 2008-12-05 2011-06-27 Abbott Lab Derivados de tieno[3,2-c]piridina como inhibidores de cinasa para utilizarse en el tratamiento de cancer.
AU2009325072A1 (en) 2008-12-12 2011-06-30 Ariad Pharmaceuticals, Inc. Azaindole derivatives as kinase inhibitors
EP2765130B1 (en) * 2009-02-25 2017-07-26 Takeda Pharmaceutical Company Limited Intermediates for use in a process of producing pyrrole compounds
US20110112101A1 (en) * 2009-03-05 2011-05-12 Sanofi-Aventis Treatment for ocular-related disorders
DK2414356T3 (en) 2009-04-03 2015-12-14 Hoffmann La Roche PROPAN-1-sulfonic acid {3- [5- (4-CHLORO-PHENYL) -1H-pyrrolo [2,3-b] pyridine-3- carbonyl] -2,4-difluorophenyl) -AMIDSAMMENSÆTNINGER AND USES THEREOF
WO2010135411A2 (en) * 2009-05-19 2010-11-25 The Regents Of The University Of Colorado Aurora-a copy number and sensitivity to inhibitors
WO2010146059A2 (en) 2009-06-16 2010-12-23 F. Hoffmann-La Roche Ag Biomarkers for igf-1r inhibitor therapy
KR101903354B1 (ko) 2009-06-17 2018-10-04 버텍스 파마슈티칼스 인코포레이티드 인플루엔자 바이러스 복제의 억제제
US8329724B2 (en) 2009-08-03 2012-12-11 Hoffmann-La Roche Inc. Process for the manufacture of pharmaceutically active compounds
FR2949467B1 (fr) 2009-09-03 2011-11-25 Sanofi Aventis Nouveaux derives de 5,6,7,8-tetrahydroindolizine inhibiteurs d'hsp90, compositions les contenant et utilisation
WO2011057022A1 (en) 2009-11-06 2011-05-12 Plexxikon, Inc. Compounds and methods for kinase modulation, and indications therefor
EP2338890A1 (en) 2009-12-22 2011-06-29 Bayer CropScience AG 4,7-Diazaindole derivatives and their use as fungicides
PE20130188A1 (es) 2009-12-23 2013-02-21 Takeda Pharmaceutical Pirrolidinonas heteroaromaticas fusionadas como inhibidores de syk
CN102869663A (zh) * 2010-01-27 2013-01-09 沃泰克斯药物股份有限公司 吡唑并吡嗪激酶抑制剂
WO2011109932A1 (en) * 2010-03-09 2011-09-15 F.Hoffmann-La Roche Ag Novel process for the manufacture of 5-halogenated-7-azaindoles
MX354212B (es) 2010-03-10 2018-02-19 Incyte Corp Derivados de piperidin-4-il azetidina como inhibidores de janus cinasa 1 (jak1).
US8518945B2 (en) 2010-03-22 2013-08-27 Hoffmann-La Roche Inc. Pyrrolopyrazine kinase inhibitors
US8481541B2 (en) * 2010-03-22 2013-07-09 Hoffmann-La Roche Inc. Pyrrolopyrazine kinase inhibitors
KR20130083387A (ko) 2010-05-20 2013-07-22 에프. 호프만-라 로슈 아게 Syk 및 jak 억제제로서 피롤로피라진 유도체
WO2011144585A1 (en) * 2010-05-20 2011-11-24 F. Hoffmann-La Roche Ag Pyrrolo [2, 3 - b] pyrazine - 7 - carboxamide derivatives and their use as jak and syk inhibitors
US20110288107A1 (en) 2010-05-21 2011-11-24 Bhavnish Parikh Topical formulation for a jak inhibitor
JP6086326B2 (ja) * 2010-05-24 2017-03-01 ユニヴァーシティー オブ ロチェスター 二環式ヘテロアリールキナーゼ阻害剤および使用方法
WO2011153049A1 (en) 2010-06-02 2011-12-08 The Trustees Of The University Of Pennsylvania Methods and use of compounds that bind to her2/neu receptor complex
WO2011153050A1 (en) 2010-06-02 2011-12-08 The Trustees Of The University Of Pennsylvania Methods and use of compounds that bind to her2/neu receptor complex
JP2014501705A (ja) * 2010-11-01 2014-01-23 ポートラ ファーマシューティカルズ， インコーポレイテッド Ｓｙｋ調節剤としてのベンズアミドおよびニコチンアミド
CA2818542A1 (en) 2010-11-19 2012-05-24 Incyte Corporation Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
KR20140014110A (ko) 2010-12-16 2014-02-05 버텍스 파마슈티칼스 인코포레이티드 인플루엔자 바이러스 복제의 억제제
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
EA028821B9 (ru) 2011-02-07 2018-10-31 Плексксикон, Инк. Соединения и способы для модуляции киназ, а также показания к их применению
TWI558702B (zh) 2011-02-21 2016-11-21 普雷辛肯公司 醫藥活性物質的固態形式
CN106619647A (zh) 2011-02-23 2017-05-10 因特利凯有限责任公司 激酶抑制剂的组合及其用途
EA201391626A1 (ru) 2011-05-04 2014-03-31 Ариад Фармасьютикалз, Инк. Соединения для ингибирования клеточной пролиферации в egfr-стимулированных типах рака
EP2706853B1 (en) 2011-05-10 2017-06-14 Merck Sharp & Dohme Corp. Aminopyrimidines as syk inhibitors
US9145391B2 (en) 2011-05-10 2015-09-29 Merck Sharp & Dohme Corp. Bipyridylaminopyridines as Syk inhibitors
CA2834062A1 (en) 2011-05-10 2012-11-15 Merck Sharp & Dohme Corp. Pyridyl aminopyridines as syk inhibitors
WO2012177606A1 (en) 2011-06-20 2012-12-27 Incyte Corporation Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
WO2012177714A1 (en) 2011-06-22 2012-12-27 Takeda Pharmaceutical Company Limited Substituted 6-aza-isoindolin-1-one derivatives
EP2729465A2 (en) 2011-07-05 2014-05-14 Vertex Pharmaceuticals Incorporated Processes and intermediates for producing azaindoles
WO2013012909A1 (en) 2011-07-20 2013-01-24 Abbott Laboratories Kinase inhibitor with improved aqueous solubility
UA118010C2 (uk) 2011-08-01 2018-11-12 Вертекс Фармасьютікалз Інкорпорейтед Інгібітори реплікації вірусів грипу
DE102011111400A1 (de) * 2011-08-23 2013-02-28 Merck Patent Gmbh Bicyclische heteroaromatische Verbindungen
ME03332B (me) 2011-09-14 2019-10-20 Samumed Llc Indazol-3-karboksamidi i njihova upotreba kao inhibitora signalnog puta wnt/b-katenina
EP2763974B1 (en) 2011-10-05 2016-09-14 Merck Sharp & Dohme Corp. Phenyl carboxamide-containing spleen tyrosine kinase (syk) inhibitors
EP2763976B1 (en) 2011-10-05 2016-05-18 Merck Sharp & Dohme Corp. 2-pyridyl carboxamide-containing spleen tyrosine kinase (syk) inhibitors
EP2763975B1 (en) 2011-10-05 2016-04-06 Merck Sharp & Dohme Corp. 3-pyridyl carboxamide-containing spleen tyrosine kinase (syk) inhibitors
PH12017500997A1 (en) 2012-04-04 2018-02-19 Samumed Llc Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof
IN2012CH01573A (cg-RX-API-DMAC7.html) 2012-04-20 2015-07-10 Advinus Therapeutics Ltd
AU2013204563B2 (en) 2012-05-05 2016-05-19 Takeda Pharmaceutical Company Limited Compounds for inhibiting cell proliferation in EGFR-driven cancers
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
BR112014030812B1 (pt) 2012-06-13 2022-11-08 Incyte Holdings Corporation Compostos tricíclicos substituídos como inibidores de fgfr, seus usos, composição farmacêutica e método para inibir uma enzima fgfr
EP2863913B1 (en) 2012-06-20 2018-09-12 Merck Sharp & Dohme Corp. Imidazolyl analogs as syk inhibitors
WO2013192125A1 (en) 2012-06-20 2013-12-27 Merck Sharp & Dohme Corp. Pyrazolyl derivatives as syk inhibitors
US9416111B2 (en) 2012-06-22 2016-08-16 Merck Sharp & Dohme Corp. Substituted diazine and triazine spleen tyrosine kinease (Syk) inhibitors
US9376418B2 (en) 2012-06-22 2016-06-28 Merck Sharp & Dohme Corp. Substituted pyridine spleen tyrosine kinase (SYK) inhibitors
CN102718694B (zh) * 2012-06-27 2014-04-02 上海大学 3-氰基取代吲哚化合物及其合成方法
WO2014026125A1 (en) 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
WO2014031438A2 (en) 2012-08-20 2014-02-27 Merck Sharp & Dohme Corp. SUBSTITUTED PHENYL SPLEEN TYROSINE KINASE (Syk) INHIBITORS
ES2880814T3 (es) 2012-11-15 2021-11-25 Incyte Holdings Corp Formas de dosificación de liberación sostenida de ruxolitinib
EP2738172A1 (en) * 2012-11-28 2014-06-04 Almirall, S.A. New bicyclic compounds as crac channel modulators
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
WO2014110086A2 (en) 2013-01-08 2014-07-17 Samumed, Llc 3-(benzoimidazol-2-yl)-indazole inhibitors of the wnt signaling pathway and therapeutic uses thereof
US9468681B2 (en) 2013-03-01 2016-10-18 California Institute Of Technology Targeted nanoparticles
EP3489239B1 (en) 2013-03-06 2021-09-15 Incyte Holdings Corporation Processes and intermediates for making a jak inhibitor
KR102194745B1 (ko) 2013-03-13 2020-12-24 포르마 세라퓨틱스 인크. Ｆａｓｎ 억제용 신규 화합물 및 조성물
WO2014139328A1 (en) * 2013-03-14 2014-09-18 Abbvie Inc. Pyrrolo[2,3-b]pyridine cdk9 kinase inhibitors
AR101528A1 (es) * 2013-03-14 2016-12-28 Abbvie Inc Inhibidores de cdk9 quinasa de pirrolo[2,3-b]piridina
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
ME03015B (me) 2013-04-19 2018-10-20 Incyte Holdings Corp Biciklični heterocikli kao fgfr inhibitori
TWI789516B (zh) 2013-08-07 2023-01-11 美商英塞特公司 Jak1抑制劑之持續釋放劑型
WO2015029447A1 (ja) * 2013-08-30 2015-03-05 興和株式会社 光学活性カルビノール化合物の製造方法
HRP20191525T1 (hr) 2013-11-13 2019-11-29 Vertex Pharma Inhibitori replikacije virusa influence
LT3421468T (lt) 2013-11-13 2021-01-11 Vertex Pharmaceuticals Incorporated Gripo virusų replikacijos inhibitorių paruošimo būdai
WO2016040180A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
WO2016040190A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof
WO2016040184A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
WO2016040185A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 2-(1h-indazol-3-yl)-3h-imidazo[4,5-b]pyridine and therapeutic uses thereof
WO2016040181A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
WO2016040193A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
SG11201704685TA (en) 2014-12-11 2017-07-28 Beta Pharma Inc Substituted 2-anilinopyrimidine derivatives as egfr modulators
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
CR20170390A (es) 2015-02-20 2017-10-23 Incyte Holdings Corp Heterociclos biciclicos como inhibidores de fgfr
WO2016134294A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
JP6704416B2 (ja) 2015-05-13 2020-06-03 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ インフルエンザウイルスの複製の阻害剤を調製する方法
WO2016183120A1 (en) 2015-05-13 2016-11-17 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
JP6914860B2 (ja) 2015-07-01 2021-08-04 カリフォルニア インスティチュート オブ テクノロジー カチオン性粘液酸ポリマー系デリバリーシステム
US10195185B2 (en) 2015-08-03 2019-02-05 Samumed, Llc 3-(1H-imidazo[4,5-C]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
US10206908B2 (en) 2015-08-03 2019-02-19 Samumed, Llc 3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof
WO2017024026A1 (en) 2015-08-03 2017-02-09 Samumed, Llc 3-(1h-indol-2-yl)-1h-pyrazolo[3,4-c]pyridines and therapeutic uses thereof
WO2017024010A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof
WO2017023986A1 (en) 2015-08-03 2017-02-09 Samumed, Llc 3-(1h-indol-2-yl)-1h-indazoles and therapeutic uses thereof
US10206909B2 (en) 2015-08-03 2019-02-19 Samumed, Llc 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
WO2017024003A1 (en) 2015-08-03 2017-02-09 Samumed, Llc 3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
US10285983B2 (en) 2015-08-03 2019-05-14 Samumed, Llc 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[3,4-B] pyridines and therapeutic uses thereof
US10188634B2 (en) 2015-08-03 2019-01-29 Samumed, Llc 3-(3H-imidazo[4,5-C]pyridin-2-yl)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
US10226453B2 (en) 2015-08-03 2019-03-12 Samumed, Llc 3-(1H-indol-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
WO2017023975A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-pyrrolo[2,3-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridines and therapeutic uses thereof
US10329309B2 (en) 2015-08-03 2019-06-25 Samumed, Llc 3-(3H-imidazo[4,5-B]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
US10226448B2 (en) 2015-08-03 2019-03-12 Samumed, Llc 3-(1H-pyrrolo[3,2-C]pyridin-2-yl)-1H-pyrazolo[3,4-B]pyridines and therapeutic uses thereof
US10519169B2 (en) 2015-08-03 2019-12-31 Samumed, Llc 3-(1H-pyrrolo[2,3-C]pyridin-2-yl)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
WO2017023980A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridines and therapeutic uses thereof
US10350199B2 (en) 2015-08-03 2019-07-16 Samumed, Llc 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof
US10392383B2 (en) 2015-08-03 2019-08-27 Samumed, Llc 3-(1H-benzo[d]imidazol-2-yl)-1H-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
WO2017064217A1 (en) * 2015-10-13 2017-04-20 Institut National De La Sante Et De La Recherche Medicale (Inserm) Sibiriline derivatives for use for preventing and/or treating disorders associated with cellular necroptosis
CN108473491A (zh) 2015-11-06 2018-08-31 萨穆梅德有限公司 2-(1h-吲唑-3-基)-3h-咪唑并[4,5-c]吡啶以及其抗炎用途
WO2017100201A1 (en) * 2015-12-07 2017-06-15 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
AR107030A1 (es) * 2015-12-09 2018-03-14 Padlock Therapeutics Inc Inhibidores aza-bencimidazol de pad4
US20190060286A1 (en) 2016-02-29 2019-02-28 University Of Florida Research Foundation, Incorpo Chemotherapeutic Methods
SI3464285T1 (sl) 2016-06-01 2023-02-28 Biosplice Therapeutics, Inc. Postopek za pripravo N-(5-(3-(7-(3-fluorofenil)-3H-imidazo(4,5-C)piridin-2-il)-1H-indazol-5- il)piridin-3-il)-3-metilbutanamida
WO2017207481A1 (en) 2016-06-01 2017-12-07 Bayer Animal Health Gmbh Substituted indazoles ueful for treatment and prevention of allergic and/or inflammatory diseases in animals
CN106008306A (zh) * 2016-06-28 2016-10-12 山东大学 取代吲哚类衍生物及其制备方法与应用
BR112019008061A2 (pt) 2016-10-21 2019-09-17 Samumed Llc métodos de uso de indazol-3-carboxamidas e seu uso como inibidores da via de sinalização de wnt/b-catenina
WO2018085865A1 (en) 2016-11-07 2018-05-11 Samumed, Llc Single-dose, ready-to-use injectable formulations
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
WO2018226846A1 (en) 2017-06-07 2018-12-13 Plexxikon Inc. Compounds and methods for kinase modulation
CA3067044A1 (en) 2017-06-16 2018-12-20 Beta Pharma, Inc. Pharmaceutical formulations of n-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1h-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide and salts thereof
AR113922A1 (es) 2017-12-08 2020-07-01 Incyte Corp Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas
HRP20220510T1 (hr) 2018-01-30 2022-05-27 Incyte Corporation Postupci za pripravu (1-(3-fluoro-2-(trifluorometil)izonikotinil) piperidin-4-ona)
HUE067471T2 (hu) 2018-03-30 2024-10-28 Incyte Corp Gennyes verejtékmirigy-gyulladás kezelése jak inhibitorok alkalmazásával
CN108358894B (zh) * 2018-04-26 2021-05-07 四川大学 一种抑制组蛋白乙酰转移酶的化合物及其制备方法与应用
TW201946630A (zh) 2018-05-04 2019-12-16 美商英塞特公司 Fgfr抑制劑之鹽
SG11202010636VA (en) 2018-05-04 2020-11-27 Incyte Corp Solid forms of an fgfr inhibitor and processes for preparing the same
JP7483193B2 (ja) 2018-06-13 2024-05-15 カリフォルニア・インスティテュート・オブ・テクノロジー 血脳バリアを越えるためのナノ粒子とそれを用いた治療法
TWI767148B (zh) 2018-10-10 2022-06-11 美商弗瑪治療公司 抑制脂肪酸合成酶(fasn)
CN113382633A (zh) 2018-10-29 2021-09-10 福马治疗股份有限公司 (4-(2-氟-4-(1-甲基-1H-苯并[d]咪唑-5-基)苯甲酰基)哌嗪-1-基)(1-羟基环丙基)甲酮的固体形式
ES2974634T3 (es) 2018-12-21 2024-06-28 Celgene Corp Inhibidores de tienopiridinas de RIPK2
EP3906026A4 (en) 2018-12-31 2022-10-19 Biomea Fusion, LLC Irreversible inhibitors of menin-mll interaction
TW202043205A (zh) 2018-12-31 2020-12-01 美商拜歐米富士恩有限公司 Menin-mll相互作用之抑制劑
EP3917911A1 (en) * 2019-01-31 2021-12-08 Kyorin Pharmaceutical Co., Ltd. 15-pgdh inhibitors
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
CN111171001B (zh) * 2019-05-16 2022-04-29 百济神州(苏州)生物科技有限公司 一种parp抑制剂中间体的结晶方法
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US12122767B2 (en) 2019-10-01 2024-10-22 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
GEP20247679B (en) 2019-10-14 2024-10-10 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
EP4069696A1 (en) 2019-12-04 2022-10-12 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
AU2020395185A1 (en) 2019-12-04 2022-06-02 Incyte Corporation Derivatives of an FGFR inhibitor
WO2021146424A1 (en) 2020-01-15 2021-07-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
JP2023512647A (ja) * 2020-01-30 2023-03-28 アニマ バイオテック インコーポレイテッド コラーゲン１翻訳阻害剤およびその使用方法
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
EP4323405A1 (en) 2021-04-12 2024-02-21 Incyte Corporation Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
TW202313611A (zh) 2021-06-09 2023-04-01 美商英塞特公司 作為ｆｇｆｒ抑制劑之三環雜環
CA3220155A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
EP4384179A1 (en) 2021-08-11 2024-06-19 Biomea Fusion, Inc. Covalent inhibitors of menin-mll interaction for diabetes mellitus
TW202313004A (zh) 2021-08-20 2023-04-01 美商拜歐米富士恩股份有限公司 Ｍｅｎｉｎ－ｍｌｌ相互作用之不可逆抑制劑的結晶形式
EP4561567A2 (en) * 2022-07-28 2025-06-04 University of Maryland, Baltimore Inhibitors of pde11a4 and methods of using same
TW202430528A (zh) 2023-01-18 2024-08-01 美商拜歐米富士恩股份有限公司 Ｎ－［４－［４－（４－嗎啉基）－７ｈ－吡咯並［２，３－ｄ］嘧啶－６－基］苯基］－４－［［３（ｒ）－［（１－氧代－２－丙烯－１－基）氨基］－１－哌啶基］甲基］－２－吡啶甲醯胺的結晶形式作為ｍｅｎｉｎ－ｍｌｌ相互作用的共價抑制劑

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB966264A (en) 1961-08-31 1964-08-06 Distillers Co Yeast Ltd Production of alkyl pyridines
GB1141949A (en) * 1966-02-23 1969-02-05 Sterling Drug Inc 7-azaindole derivatives
US3992392A (en) * 1973-04-27 1976-11-16 The Ohio State University Research Foundation Synthesis of indoles from anilines and intermediates therein
EP0405602A1 (en) 1989-06-30 1991-01-02 Laboratorios Vinas S.A. New Zinc derivatives of anti-inflammatory drugs having improved therapeutic activity
SE9100920D0 (sv) 1991-03-27 1991-03-27 Astra Ab New active compounds
FR2687402B1 (fr) 1992-02-14 1995-06-30 Lipha Nouveaux azaindoles, procedes de preparation et medicaments les contenant.
JP3119758B2 (ja) 1993-02-24 2000-12-25 日清製粉株式会社 ７−アザインドール誘導体及びこれを有効成分とする抗潰瘍薬
US6756388B1 (en) 1993-10-12 2004-06-29 Pfizer Inc. Benzothiophenes and related compounds as estrogen agonists
US5521213A (en) 1994-08-29 1996-05-28 Merck Frosst Canada, Inc. Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2
DE4435477A1 (de) * 1994-10-04 1996-04-11 Bayer Ag Cycloalkano-indol- und -azaindol-derivate
US5589482A (en) 1994-12-14 1996-12-31 Pfizer Inc. Benzo-thiophene estrogen agonists to treat prostatic hyperplasia
GB2298199A (en) 1995-02-21 1996-08-28 Merck Sharp & Dohme Synthesis of azaindoles
FR2732969B1 (fr) 1995-04-14 1997-05-16 Adir Nouveaux composes pyridiniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
AR004010A1 (es) 1995-10-11 1998-09-30 Glaxo Group Ltd Compuestos heterociclicos
EP0787730B1 (de) 1996-01-30 2001-08-01 Ciba SC Holding AG Polymerisierbare Diketopyrrolopyrrole und damit hergestellte Polymere
WO1998002437A1 (en) * 1996-07-13 1998-01-22 Glaxo Group Limited Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors
EP0927167A1 (en) 1996-08-14 1999-07-07 Warner-Lambert Company 2-phenyl benzimidazole derivatives as mcp-1 antagonists
DK0948495T3 (da) 1996-11-19 2004-06-01 Amgen Inc Aryl- og heteroarylsubstitueret, kondenseret pyrrol som antiinflammatoriske midler
US6312835B1 (en) 1997-02-13 2001-11-06 Queen's University At Kingston Luminescent compounds and methods of making and using same
WO1998047899A1 (en) * 1997-04-24 1998-10-29 Ortho-Mcneil Corporation, Inc. Substituted pyrrolopyridines useful in the treatment of inflammatory diseases
HUP0100348A3 (en) * 1997-10-20 2002-12-28 Hoffmann La Roche Bicycles containing a six menbered ring with one or two nitrogen atoms, process for their preparation, use of them, pharmaceutical compositions containing the same and intermediates
WO1999045016A2 (en) 1998-03-06 1999-09-10 Metabasis Therapeutics, Inc. Novel prodrugs for phosphorus-containing compounds
JP2002510684A (ja) 1998-04-02 2002-04-09 メルク エンド カムパニー インコーポレーテッド 性腺刺激ホルモン放出ホルモン拮抗薬
AU3118399A (en) 1998-04-02 1999-10-25 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
AU3210799A (en) 1998-04-02 1999-10-25 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
WO1999051234A1 (en) 1998-04-02 1999-10-14 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
AU3117899A (en) 1998-04-02 1999-10-25 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
US6025366A (en) 1998-04-02 2000-02-15 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
JP2002510685A (ja) 1998-04-02 2002-04-09 メルク エンド カムパニー インコーポレーテッド 性腺刺激ホルモン放出ホルモン拮抗薬
JP2002514635A (ja) 1998-05-12 2002-05-21 アメリカン・ホーム・プロダクツ・コーポレイション インスリン耐性および高血糖の処置に有用なビフェニルオキソ−酢酸
ATE482945T1 (de) * 1998-05-26 2010-10-15 Chugai Pharmaceutical Co Ltd Heterozyklische indolderivate und mono- oder diazaindol-derivate
US6232320B1 (en) 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
SE510289C2 (sv) 1998-06-09 1999-05-10 Car O Liner Ab Fastspänningsanordning för fordon vid en riktbänk
DE69928414T2 (de) * 1998-09-18 2006-08-03 Abbott Gmbh & Co. Kg 4-aminopyrrolopyrimidine als kinaseinhibitoren
KR100657780B1 (ko) 1998-12-31 2006-12-15 아벤티스 파마슈티칼스 인크. 비보호 β-아미노 에스테르 화합물의 α-치환 방법
AU5314900A (en) 1999-06-04 2000-12-28 Elan Pharma International Limited Compositions and methods for inhibiting cell death
US6207699B1 (en) 1999-06-18 2001-03-27 Richard Brian Rothman Pharmaceutical combinations for treating obesity and food craving
PE20010306A1 (es) 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
US6387900B1 (en) 1999-08-12 2002-05-14 Pharmacia & Upjohn S.P.A. 3(5)-ureido-pyrazole derivatives process for their preparation and their use as antitumor agents
DE19951360A1 (de) 1999-10-26 2001-05-03 Aventis Pharma Gmbh Substituierte Indole
HRP20020547B1 (hr) * 1999-12-24 2011-06-30 Aventis Pharma Limited Azaindoli
YU54202A (sh) 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
EP1257546A1 (en) 2000-02-17 2002-11-20 Amgen Inc. Kinase inhibitors
DE10009000A1 (de) 2000-02-25 2001-08-30 Basf Ag Verfahren zur Herstellung substituierter Indole
CA2400923A1 (en) 2000-02-25 2001-08-30 Merck & Co., Inc. Tyrosine kinase inhibitors
GB0007657D0 (en) 2000-03-29 2000-05-17 Celltech Therapeutics Ltd Chemical compounds
WO2001079198A1 (en) 2000-04-18 2001-10-25 Agouron Pharmaceuticals, Inc. Pyrazoles for inhibiting protein kinase
BR0111544A (pt) * 2000-06-14 2003-07-01 Warner Lambert Co Heterociclos bicìclicos 6,5-fundidos
US6407259B1 (en) 2000-07-28 2002-06-18 Pfizer Inc. Process for the preparation of pyrazoles
US6897231B2 (en) 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
CA2422367C (en) 2000-09-15 2010-05-18 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
JP2004510762A (ja) 2000-10-02 2004-04-08 メルク　エンド　カムパニー　インコーポレーテッド プレニル−蛋白質トランスフェラーゼの阻害剤
GB0115109D0 (en) 2001-06-21 2001-08-15 Aventis Pharma Ltd Chemical compounds

Also Published As

Publication number Publication date
BR0210507A (pt) 2004-06-15
KR20090035650A (ko) 2009-04-09
US6897207B2 (en) 2005-05-24
SK15902003A3 (sk) 2004-06-08
NO20035476D0 (no) 2003-12-09
SI21462A (sl) 2004-10-31
CA2451678C (en) 2011-01-11
EE200400015A (et) 2004-04-15
ZA200309648B (en) 2005-03-11
RU2326880C2 (ru) 2008-06-20
PL365067A1 (en) 2004-12-27
AR036106A1 (es) 2004-08-11
GB0115109D0 (en) 2001-08-15
NZ529205A (en) 2006-04-28
AP1739A (en) 2007-05-09
JO2327B1 (en) 2006-06-28
KR100977344B1 (ko) 2010-08-20
AP2003002940A0 (en) 2003-12-31
EP1397360A1 (en) 2004-03-17
US7943616B2 (en) 2011-05-17
CN1665809A (zh) 2005-09-07
MY137099A (en) 2008-12-31
OA12637A (en) 2006-06-15
HUP0400247A2 (hu) 2005-01-28
JP2004534826A (ja) 2004-11-18
HN2002000154A (es) 2002-09-17
EP2233486A1 (en) 2010-09-29
WO2003000688A1 (en) 2003-01-03
BG108481A (bg) 2005-05-31
CA2451678A1 (en) 2003-01-03
CZ20033444A3 (en) 2004-03-17
JP4409938B2 (ja) 2010-02-03
CN100509811C (zh) 2009-07-08
KR100915289B1 (ko) 2009-09-03
RU2004101408A (ru) 2005-04-20
US20050267304A1 (en) 2005-12-01
NZ545741A (en) 2007-09-28
YU96903A (sh) 2006-08-17
PE20030155A1 (es) 2003-04-11
PA8548701A1 (es) 2003-02-14
MA27043A1 (fr) 2004-12-20
ECSP034914A (es) 2004-04-28
KR20040018284A (ko) 2004-03-02
UA85660C2 (en) 2009-02-25
TWI334417B (en) 2010-12-11
US20040053931A1 (en) 2004-03-18
HRP20031069A2 (en) 2004-04-30
IL159445A0 (en) 2004-06-01
TNSN03110A1 (en) 2005-12-23

Similar Documents

Publication Publication Date Title
UY27350A1 (es) Azaindoles
UY27516A1 (es) Bencimidazoles
PA8557101A1 (es) Benzimidazoles
ECSP045004A (es) Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades andrógeno dependientes
UY28671A1 (es) Pirido(2.3-d)pirimidina-2,4-diaminas como inhibidores de pde 2
SE0202463D0 (sv) Novel compounds
UY27418A1 (es) Formulaciones en combinación de derivados de propanol-amina sustituidos con arilo, junto con otras sustancias activas y su utilización
PA8591701A1 (es) Derivados de pirrolopirimidina
UY30274A1 (es) Derivados sustituidos de la n-(4-metil-1,3-tiazol-2-il)guanidina, formulaciones farmacéuticas conteniéndolo y aplicaciones
UA88012C2 (uk) Похідні хіназоліндіону як інгібітори parp
UY31334A1 (es) 3a,4,5,6,7,7a-hexahidro-3h-benzoimidazol y derivaods de 3a, 4,5,6,,7,7a-hexahidro-3-indol, enantiómeros, diastereoisómeros, sales farmacéuticamente aceptadas, mezclas, composiciones, preparaciones y aplicaciones de las mismas
GT199900008A (es) Compuestos 4-(2-ceto-1-benzilimidazolinil) piperidina como agonistas del receptor orl1
NO20081844L (no) Terapeutiske forbindelser
DOP2002000422A (es) Agentes antibacterianos.
ES2421948T3 (es) Compuestos y composiciones para suministrar agentes activos
CL2004000590A1 (es) Compuestos derivados de 1,3,4-oxadiazol-3-ona, 1,3,4-tiadiazol-2-ona y de 1,2,4-triazol-3-ona; composicion farmaceutica que los contiene; procedimiento de preparacion y su uso en la preparacion de un medicamento en los que esta relacionado el virus v
PA8568101A1 (es) Indolil-urea derivados de tienopiridinas utiles como agentes antiangiogenicos, y procedimientos para su uso
GT200600163A (es) Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de la depresion
UY28536A1 (es) Derivados de bencimidazol, composiciones que los contienen, preparacion y usos de los mismos.
CR9722A (es) Derivados de benzilpiperazina y su uso medico
UY29999A1 (es) "n-pirazinil-fenilsulfonamidas, procedimientos y compuestos intemedios utilizados en su preparacion, composiciones farmaceuticas que las contienen y aplicaciones"
ITMI20031144A1 (it) Analoghi del colchicoside.
SE0403118D0 (sv) New compounds 2
ECSP084914A (es) Azaindoles
SE0403117D0 (sv) New compounds 1

Legal Events

Date Code Title Description
DESI Application deemed to be withdrawn

Effective date: 20111129